bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract P2-08-30: Vitamin D as a prognostic factor in triple negative early breast cancer
Authors: Morales Murillo S , Gasol Cudos A , Veas Rodriguez J , Santacana M , Canosa Morales C , Mele Olivé J 
Published: May 2019

Abstract
Background: Triple negative breast cancer is a special phenotype where the pathological complete response (pCR) remains the most important factor but only around a 40% of patients achieve this response. We analyze if the vitamin D receptors (VDR) could be a prognostic factor not related with the histological response.
Methods: A series of 160 patients with early or locally advanced triple negative breast cancer that received neoadjuvant chemotherapy were retrospectively reviewed from 2007 to 2017. Clinicopathological and vitamin D receptors analysis were correlated to pCR.
Results: Median age was 53, median tumor size 30mm, 48% had nodal involvement, and median ki67 expression was of 70%. Androgen receptor was expressed in 28% of tumors analyzed, EGFR in 89%, CK5/6 in 63%. VDR (cytoplasmatic and nuclear) expression was determined in 56 patients, finding in 45 (80%) an expression that was considered as high. We achieved a total of 73/160 pCR (45%) with a significant median disease free survival of 178 months (log rank p: 0,0001). In the univariate analysis, the initial tumoral size, initial nodal involvement and expression of VDR was significant; and in the mutivariate model the expression of VDR maintains the level of significance ( HR: 0,138 IC 95% 0,039-0,493 p:0,002).
Conclusions: The expression of VDR in the initial tumor before starting neoadjuvant chemotherapy is a strong predictor of recurrence independently of histological response with a median disease free survival of 149 months in patients with high expression versus 62 month. Furthermore, in patients without histological response, progression-free median survival is 86 months for patients with high expression versus 35 months.
Citation Format: Morales Murillo S, Gasol Cudos A, Veas Rodriguez J, Santacana M, Canosa Morales C, Mele Olivé J. Vitamin D as a prognostic factor in triple negative early breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-30.
Abstract P2-08-32: Withdrawn
Authors: Perimbeti SP , Shrivastav R , Ward K , Styler M 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Perimbeti SP, Shrivastav R, Ward K, Styler M. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-08-32.
Abstract P2-14-21: Not presented
Authors: Lee S , Ahn SH , Lee JW , Chung IY , Ko BS , Kim HJ , Kim J , Shon G , Son BH 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Lee S, Ahn SH, Lee JW, Chung IY, Ko BS, Kim HJ, Kim J, Shon G, Son BH. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P2-14-21.
Abstract P3-03-05: Not presented
Authors: Jung S-Y , Han JH , Park SJ , Lee E-G , Lee MH , Lee ES , Kang H-S , Lee KS , Park IH , Sim SH , Jeong HJ , Kwon Y , Lee D-E , Joo J , Kim S-K , Lee S 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Jung S-Y, Han JH, Park SJ, Lee E-G, Lee MH, Lee ES, Kang H-S, Lee KS, Park IH, Sim SH, Jeong HJ, Kwon Y, Lee D-E, Joo J, Kim S-K, Lee S. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-05.
Abstract P3-03-24: ABCSG 33 - A multi center registry to evaluate the affect of macro metastasis in sentinel lymph node on survival
Authors: Strobl SA , Dubsky P , Exner R , Gnant M , Jakesz R , Tausch C , Wette V , Heck D , Luisser I , Bjelic-Radisic V , Schrenk P , Poyssl C , Mathis J , Fitzal F 
Published: May 2019

Abstract
Background:
Sentinel lymph node dissection identifies nodal positivity in early breast cancer. Trials like the ACOSOG Z0011 trial tried to show that the waiver of axillary dissection in nodal positive breast cancer (BC) has no effect on the oncologic outome, however real world data are rare and the role of adjuvant regional radiotherapy is still disputed in this respect.
Objective:
We initiated a multicenter observational registry to investigate omission of axillary lymph node dissection in nodal positive early BC.
Design and Setting:
The 18 sites participating in Austria and Switzerland included from 2014 to 2017 178 patients in this trail.
Patients:
Women with unilateral invasive lymph node positive BC with one or two sentinel lymph node makrometastases, who did not undergo axillary lymph node dissection were included.
Results:
We had a median follow up time of 3.1 years (range between 0.5 and 10.5 years), the median patient age is 63.6 years (range between 33 – 93 years). In 16.9% women had a G1 Grading, 53.1% had G2 tumor and 29.9% had a G3 tumor. Multifocality was seen in 18.1% of the patients. Luminal A tumors were seen in 16 (8.9%) and Luminal B in 82 (46.1%). Fourteen (7.8%) patients in this cohort had HER2 positive BC. In one (0.5%) local recurrence of the axilla occurred. Three (1.7%) of 178 patients died due to BC recurrence.
Conclusion:
Patients with macro metastasis in the sentinel lymph node, treated with breast conserving surgery and whole breast radiation did not have an increased risk of BC recurrence.
Therefore the authors assume that axillary dissection in patients with early stage BC and macro metastasis is not necessary in this patient cohort.
Citation Format: Strobl SA, Dubsky P, Exner R, Gnant M, Jakesz R, Tausch C, Wette V, Heck D, Luisser I, Bjelic-Radisic V, Schrenk P, Poyssl C, Mathis J, Fitzal F. ABCSG 33 - A multi center registry to evaluate the affect of macro metastasis in sentinel lymph node on survival [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-24.
Abstract P3-03-42: Withdrawn
Authors: Bundred NJ , Foden P , Riches K , Morris J , Evans A , Todd C , Bramley M , Skene A , Purushotham A , Keeley V 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Bundred NJ, Foden P, Riches K, Morris J, Evans A, Todd C, Bramley M, Skene A, Purushotham A, Keeley V. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-03-42.
Abstract P3-04-02: Not presented
Authors: Chen X , Tong Y , Chen W , Li Y , Shen K 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Chen X, Tong Y, Chen W, Li Y, Shen K. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-04-02.
Abstract P3-06-02: Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer
Authors: Nguyen B , Venet D , Lambertini M , Desmedt C , Salgado R , Horlings HM , Rothe F , Sotiriou C 
Published: May 2019

Abstract
Background: Although parity and age at first pregnancy are among the most known extrinsic factors that modulates breast cancer risk, their impact on the biology of subsequent breast cancer has never been explored in depth. In this study, we investigated the imprint of parity and age at first pregnancy on the pattern of somatic mutations, somatic copy number alterations (SCNAs), transcriptomic profiles, and tumor immune microenvironment by assessing infiltrating lymphocytes (TILs) levels of subsequent breast cancer.
Methods: A total of 313 patients with primary breast cancer with available whole genome, RNA sequencing and TILs data were included in this study. We used a multivariate analysis adjusted for age at diagnosis, pathological stage, molecular subtypes and histological subtypes. We compared nulliparous vs. parous, late parous vs. early parous, and nulliparous vs. pregnancy associated breast cancer (PABC) patients. Late and early parous patients were grouped by using the median age at first pregnancy as a cut-off value. PABC was defined as patients diagnosed up to 10 years postpartum.
Results: Genomic alterations of breast cancer were associated with age at first pregnancy but not with parity status alone. Independently of clinicopathological features, early parous patients developed tumors characterized by a higher number of Indels (Padj = 0.002), a lower frequency of CDH1 mutations (1.2% vs. 12.7%; Padj = 0.013), a higher frequency of TP53 mutations (50% vs. 22.5%; Padj = 0.010), MYC amplification (28% vs. 7%; Padj = 0.008), and a lower prevalence of mutational signature 2, putatively associated with APOBEC activity. PABC were associated with increased TILs infiltration (Padj = 0.0495).
Conclusions: These findings highlight an unprecedented link between reproductive history and the genomic landscape of subsequent breast cancer. This work advocates that reproductive history should be routinely collected in future large scale genomic studies addressing the biology of female cancers.
Citation Format: Nguyen B, Venet D, Lambertini M, Desmedt C, Salgado R, Horlings HM, Rothe F, Sotiriou C. Imprint of parity and age at first pregnancy on the genomic landscape of subsequent breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-06-02.
Abstract P3-06-20: Druggable genomic landscape of primary and metastatic breast cancers
Authors: Sun SQ 
Published: May 2019

Abstract
Background: Several studies (e.g. The Pan-Cancer Atlas) have examined the druggable genomic landscape of breast cancers and other malignancies using The Cancer Genome Atlas (TCGA). However, TCGA is representative of newly-diagnosed, treatment-naïve breast cancers, whereas genomic profiling is typically used to inform therapy for metastatic and/or pre-treated breast cancers. Here, we characterize the druggable genomic landscape of breast cancers using AACR Genomics Evidence Neoplasia Information Exchange (GENIE), a multi-institutional pragmatic cancer genomics registry.
Methods: We obtained mutation, copy-number amplification (CNA), and fusion data from GENIE, which contains de-identified genomic records from 4506 breast carcinoma and carcinoma-in-situ (CIS) tumors. We used Clinical Interpretation of Variants in Cancer (CIViC) to label the potential druggability of these mutations, CNAs, and fusions. Further, we plan to assess variations in the druggable genomic landscape of breast tumors as a function of tumor characteristics (e.g. histology, tumor mutation burden), patient characteristics (age, sex, ethnicity), and genomics assay characteristics (e.g. PCR vs. hybridization capture).
Results: In GENIE, we identified 19932 mutations, 9334 copy number amplifications (CNA), and 987 fusions in 4506 breast tumors. CNAs suggesting potential druggability were relatively common (e.g. ERBB2 amplifications in 9.9% of tumors), whereas fusions suggesting potential druggability were relatively rare (e.g. NTRK fusions in 0.1% of tumors). Mutations suggesting potential druggability were identified in ERBB2 (3.5% of tumors) and mismatch repair genes [MLH1, MSH2, MSH3, MSH6, PMS1, PMS2] (3.7% of tumors).
Conclusion: GENIE can be used to infer druggability across a cohort of breast tumors likely to be considered for approved systemic therapy at tertiary academic centers. This may inform use of genomic assays and/or design of clinical trials for patients with breast tumors.
*The author would like to acknowledge the American Association for Cancer Research and its financial and material support in the development of the AACR Project GENIE registry, as well as members of the consortium for their commitment to data sharing. Interpretations are the responsibility of study authors.
Citation Format: Sun SQ. Druggable genomic landscape of primary and metastatic breast cancers [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-06-20.
Abstract P3-07-01: Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival (ARTEMIS)
Authors: Seth S , Huo L , Rauch G , Lau R , Gilcrease M , Adrada B , Piwnica-Worms H , Symmans WF , Draetta G , Futreal AP , Moulder S , Chang JT 
Published: May 2019

Abstract
Triple-negative breast cancer is a highly diverse group of cancers, with poor prognosis, and currently, there are no targeted drugs available in the clinic. In TNBC around 50% percent of the patients respond to chemotherapy, while, the other 50% percent relapse with poor prognosis. There is a need to understand better the targetable mechanisms driving TNBC via integrative analysis of gene-expression, copy-number, and mutational data.
Samples from 220 triple-negative breast cancer (TNBC) pts treated with NACT were prioritized for transcriptomic and genomic profiling. Non-negative matrix factorization was used on array-based profiling to identify six robust (ARTEMIS) subtypes. Comparing ARTEMIS subtypes with Vanderbilt subtypes, revealed significant overlap with 4/6 clusters while identifying two new clusters. Logistic regression on ssGSEA scores vs. subtypes revealed several pathways, selectively enriched specific subtypes. CL1/IM (Immune subtype), was enriched in INFg and INFa, while CL2 (MYC/mTOR), showed enrichment of several proliferation-related pathways. In addition, LAR and M (Mesenchymal) pts formed overlapping clusters, using either method.
Two new subtypes did not associate significantly with any of the previous subtypes. The majority of the tumors from the Vanderbilt BL2 and MSL were reclassified into a CL5 (ANGIO) cluster, which was enriched in angiogenesis geneset, including targetable genes like VEGF and FGFR. Also, an MYO (CL3) subtype was identified, with myogenesis-related genes. Of note, TIL (tumor infiltrating lymphocytes) and LAR quantification using IHC were associated with respective ARTEMIS subtypes. Finally, the IM subtype was significantly associated with higher rates of RCB 0-I and the M (CL4) subtype was associated with higher rates of RCB II-III, irrespective of the neoadjuvant treatment regimen.
ARTEMIS subtypes are a novel classification system for TNBC that is focused on therapeutic translation. Further, we show a possibility to classify previously un-classified (UNS) tumors, which will be validated using additional cohorts (TCGA/METABRIC).
Citation Format: Seth S, Huo L, Rauch G, Lau R, Gilcrease M, Adrada B, Piwnica-Worms H, Symmans WF, Draetta G, Futreal AP, Moulder S, Chang JT. Towards a therapeutically relevant subtyping scheme for triple-negative breast cancer (TNBC), profiling results from A Randomized, TNBC Enrolling trial to confirm Molecular profiling Improves Survival (ARTEMIS) [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-07-01.
Abstract P3-07-05: Not presented
Authors: Hardeman A , Grushko T , Clayton W , Hurley I , Khramtsova G , Parker J , Perou C , Olopade O 
Published: May 2019

Abstract
This abstract was not presented at the conference.
Citation Format: Hardeman A, Grushko T, Clayton W, Hurley I, Khramtsova G, Parker J, Perou C, Olopade O. Not presented [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-07-05.
Abstract P3-07-11: Withdrawn
Authors: Jackson HW , Fischer JR , Zanotelli VR , Soysal SD , Simone M , Weber WP , Bodenmiller B 
Published: May 2019

Abstract
This abstract was withdrawn by the authors.
Citation Format: Jackson HW, Fischer JR, Zanotelli VR, Soysal SD, Simone M, Weber WP, Bodenmiller B. Withdrawn [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-07-11.
Abstract P3-08-22: Oncotype Dx recurrence score risk groups according to Ki67, a predictor to be considered
Authors: Namuche F , Ruiz R , Morante Z , Aguilar A , Gomez H 
Published: May 2019

Abstract
Background
The gene expression profiling assay OncotypeDx (ODx) prognosticates the risk of estrogen receptor positive (ER+) breast cancer (BC) recurrence and assesses the likely benefit from adjuvant chemotherapy in addition to endocrine therapy. There have been several attempts to develop algorithms that provide similar outcome prediction to the ODx assay with the use of routine clinicopathological characteristics. Ki67 is frequently incorporated into these assessments, although there is no standard cut-off for its use.
Methods
We retrospectively reviewed the electronic medical records of 330 patients with early stage ER+ BC for whom ODx recurrence score (RS) was available. Patients were diagnosed and treated at two specialized cancer centers between 2014 and 2017.
Our objective was to determine the ki67's median differences between ODx risk groups.
We used Spearman rho for the correlation between Ki67 and ODx score and used Kruskal-Wallis test for compare medians, pairwaise comparison for the intergroup relations.
Results
Mean age at diagnosis was 57.42 years (range 28-89). Mean tumor diameter was 15.67 mm. 78.9% were intermediate histologic grade and 9.7% patients had lymph node involvement. Median expression of ER and PR were 90% (5-100) and 70% (0-100), respectively. We assessed the correlation between Ki67 and ODx score, with a pearson r:0.31, p&lt;0.001. The data showed a directly proportional trend between Ki67 and ODx score.
Median Ki67 was 20 (1-100). According to ODX RS, 61.5% of tumors were low risk, 30.3% were intermediate risk and, 8.2% were high risk. Median Ki67 within each category group is as follows: low: 15 (IQR:15), intermediate: 20 (IQR:18) and high: 40 (IQR:35), with a statistically significant difference between medians (p&lt;0.001). In the Pairwise comparison intergroup the data showed: Low-Intermediate (p&lt;0.05), Low-High (p&lt;0.001), Intermediate-High (p&lt;0.001).
Conclusions
The data showed directly proportional trend between Ki67 and ODx score. In our population there is a statistically significant difference between Ki67 medians according to ODx risk groups.
Citation Format: Namuche F, Ruiz R, Morante Z, Aguilar A, Gomez H. Oncotype Dx recurrence score risk groups according to Ki67, a predictor to be considered [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-08-22.
Abstract P3-12-06: TOxicities of Locoregional Radiotherapy Associated with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation
Authors: Clément-Zhao A , Tanguy M-L , Cottu P , De La Lande B , Bontemps P , Lemanski C , Baumann P , Levy C , Peignaux K , Reynaud-Bougnoux A , Gobillion A , Kirova Y 
Published: May 2019

Abstract
Background and Purpose: Recent phase 3 clinical trials have evaluated the addition of bevacizumab (B) to standard chemotherapy in the treatment of patients with non-metastatic breast cancer. But few data are available about the tolerance of B with locoregional radiation therapy (RT). The objective was to evaluate the 5 years late toxicities of the concurrent B and RT in non-metastatic breast cancer.
Material and methods: This is a multicenter prospective study including non-metastatic breast cancer patients enrolled in phase 3 clinical trials evaluating B with concurrent RT (BEATRICE, BETH, BEVERLY 1, BERVERLY 2) versus RT alone. All patients received neo-adjuvant or adjuvant chemotherapy and normo-fractionated breast or chest wall RT, with or without regional lymph nodes RT. B was administrated as an equivalent of 5 mg/kg every week for 1 year. The safety profile (using the Common Terminology Criteria for Adverse Events version 3.0) was evaluated at 1, 3 and 5 years after the completion of radiotherapy.
Results: From October 2007 to January 2012, 151 patients totally included. Median follow-up was 60 months (36-84) and 5 years late toxicities were available for 104 patients (46 with B and RT, 58 with RT alone). Median age was 51 (22-81). 61% of patients received regional lymph nodes RT. The majority of tumor was triple negative (65.6%), tumor size &lt;2cm (50%) and nodal status negative (63.8%). Median total dose of B was 15000 mg (13200 – 18550) and median duration was 11.2 months (11-12.6). No grade ≥3 toxicity was observed. Only 16 patients had grade 1-2 toxicities (8 treated with B and RT, 8 with RT alone): n=4 (3.8%) had grade 1 pain, n=5 (4.8%) had grade 1-2 fibrosis, n=1 (1%) had grade 2 telangiectasia and n=5 (4.8%) had grade 1-2 lymphoedema. No significant difference between the 2 arms was observed. One patient of 46 evaluated had Left Ventricular Ejection Fraction inferior to 50%. At 5 years, overall survival was 93.8%, disease free-survival 89% and locoregional free-survival 93.1 %.
Conclusion: Concurrent B and locoregional RT provides acceptable 5-years toxicities in patients with non-metastatic breast cancer. No grade ≥3 toxicity was observed.
Citation Format: Clément-Zhao A, Tanguy M-L, Cottu P, De La Lande B, Bontemps P, Lemanski C, Baumann P, Levy C, Peignaux K, Reynaud-Bougnoux A, Gobillion A, Kirova Y. TOxicities of Locoregional Radiotherapy Associated with Bevacizumab in patients with non-metastatic breast cancer (TOLERAB): Final long-term evaluation [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P3-12-06.